ForSight Robotics Raises $125M for Ophthalmic Robotic Surgery

ForSight Robotics, an Israeli startup in the ophthalmic robotic surgery field, has successfully completed a $125 million Series B funding round led by Eclipse. This significant investment will accelerate the next growth phase for the ORYOM™ Platform, the world’s first robotic surgery platform designed to enhance surgical precision, increase patient access to high-quality treatment, and reduce the physical burden on surgeons.

The ORYOM™ Platform leverages advanced artificial intelligence (AI) algorithms, computer vision, and micromechanics to deliver unprecedented dexterity and maneuverability. It is specifically designed to address the growing demand for ophthalmic surgeries, particularly cataract procedures. The platform can reach any point within the human eye, allowing surgeons to navigate complex angles and access both the anterior and posterior segments, making it suitable for a wide range of ophthalmic conditions, including glaucoma and retinal surgeries.

The global shortage of ophthalmologists is a critical issue. Currently, there are only 31.7 ophthalmologists per million people, and only 14.1 cataract surgeons per million. By 2035, the industry is expected to see a 12% decline in ophthalmologists, while demand for surgeries is projected to increase by 24%. Over 600 million patients suffer from cataracts, but only 30 million receive surgical treatment annually. The ORYOM™ Platform aims to bridge this gap by providing consistent and precise surgical outcomes, thereby increasing the number of patients who can receive the care they need.

In addition to Eclipse, the funding round included significant participation from an undisclosed strategic investor, Dr. Fred Moll, the Adani Group, Reiya Ventures, and other existing investors. This brings ForSight Robotics' total funding to $195 million. The company is now preparing to launch its first-in-human clinical trials this year, marking a significant milestone in the development of robotic ophthalmic surgery.

The investment will also support the expansion of ForSight Robotics' R&D capabilities and the development of additional applications for the ORYOM™ Platform. As the platform evolves, it is expected to revolutionize the field of ophthalmic surgery, making high-quality care more accessible and reducing the physical strain on surgeons. With the global demand for ophthalmic surgeries on the rise, the ORYOM™ Platform is poised to play a crucial role in meeting these needs and improving patient outcomes.